{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T18:25:31Z","timestamp":1788200731161,"version":"build-2803163510"},"reference-count":35,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T00:00:00Z","timestamp":1719273600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","award":["NNF19OC0058259"],"award-info":[{"award-number":["NNF19OC0058259"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Danish women\u2014who were HPV-vaccinated as girls\u2014are now reaching an age where they are invited to cervical cancer screening. Because of their expected lower cervical cancer risk, we must reassess our screening strategies. We analyzed Danish HPV-vaccinated women\u2019s outcomes after the first screening test at age 23.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods and findings<\/jats:title>\n<jats:p>Our study was embedded in Danish routine cytology-based screening. We conducted an observational study and included women born in 1994, offered the 4-valent HPV vaccine at age 14, and subsequently invited to screening at age 23. Cervical cytology was used for diagnostics and clinical management. Residual material was HPV tested with Cobas\u00ae 4800\/6800. The most severe histology diagnosis within 795 days of screening was found through linkage with the Danish National Pathology Register. We calculated the number of women undergoing follow-up (repeated testing and\/or colposcopy) per detected cervical intraepithelial neoplasia (CIN2+). A total of 6021 women were screened; 92% were HPV-vaccinated; 12% had abnormal cytology; 35% were high-risk HPV-positive, including 0.9% HPV16\/18 positive, and 20% had follow-up. In women that were cytology-abnormal and HPV-positive (Cyt+\/HPV+), 610 (98.5%) had been followed up, and 138 CIN2+ cases were diagnosed, resulting in 4.4 (95% CI 3.9\u20135.2) women undergoing follow-up per detected CIN2+. In contrast to recommendations, 182 (12.2%) cytology-normal and HPV-positive (Cyt-\/HPV+) women were followed up within 795 days, and 8 CIN2+ cases were found, resulting in 22.8 (95% CI 13.3\u201359.3) women undergoing follow-up per detected CIN2+.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Overall, HPV prevalence was high in HPV-vaccinated women, but HPV16\/18 had largely disappeared. In the large group of cytology-normal and HPV-positive women, 23 had been followed up per detected CIN2+ case. Our data indicated that primary HPV screening of young HPV-vaccinated women would require very effective triage methods to avoid an excessive follow-up burden.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Trial registration<\/jats:title>\n<jats:p><jats:bold>Trial registration number:<\/jats:bold> <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT0304955\" xlink:type=\"simple\">NCT0304955<\/jats:ext-link>.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0306044","type":"journal-article","created":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T18:39:24Z","timestamp":1719340764000},"page":"e0306044","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":7,"title":["Screening outcome of HPV-vaccinated women: Data from the Danish Trial23 cohort study"],"prefix":"10.1371","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0085-9109","authenticated-orcid":true,"given":"Mette Hartmann","family":"Nonboe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George Maria","family":"Napolitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Kann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4074-6504","authenticated-orcid":true,"given":"Berit","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Holten","family":"Bennetsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanne","family":"Christiansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Poulsgaard","family":"Frandsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Rygaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rouzbeh","family":"Salmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeppe Bennekou","family":"Schroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsebeth","family":"Lynge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,6,25]]},"reference":[{"key":"pone.0306044.ref001","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F","article-title":"Human Papillomavirus Is a Necessary Cause of Invasive Cervical Cancer Worldwide","volume":"189","author":"J Walboomers","year":"1999","journal-title":"Journal of Pathology"},{"key":"pone.0306044.ref002","author":"IARC","journal-title":"List of Classifications\u2013IARC Monographs on the Identification of Carcinogenic Hazards to Humans"},{"key":"pone.0306044.ref003","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/jnci\/djp534","article-title":"Impact of Human Papillomavirus (HPV)-6\/11\/16\/18 Vaccine on All HPV-Associated Genital Diseases in Young Women.","volume":"102","author":"N Munoz","year":"2010","journal-title":"Journal of the National Cancer Institute"},{"key":"pone.0306044.ref004","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1056\/NEJMoa1917338","article-title":"HPV Vaccination and the Risk of Invasive Cervical Cancer.","volume":"383","author":"J Lei","year":"2020","journal-title":"New England Journal of Medicine"},{"key":"pone.0306044.ref005","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1093\/jnci\/djab080","article-title":"Real-World Effectiveness of Human Papillomavirus Vaccination Against Cervical Cancer.","volume":"113","author":"SK Kjaer","year":"2021","journal-title":"JNCI: Journal of the National Cancer Institute."},{"key":"pone.0306044.ref006","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S0140-6736(13)62218-7","article-title":"Efficacy of HPV-based screening for prevention of invasive cervical cancer: Follow-up of four European randomised controlled trials","volume":"383","author":"G Ronco","year":"2014","journal-title":"The Lancet"},{"key":"pone.0306044.ref007","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.cmi.2019.09.006","article-title":"Primary HPV-based cervical cancer screening in Europe: implementation status, challenges, and future plans","volume":"26","author":"PJ Maver","year":"2020","journal-title":"Clinical Microbiology and Infection"},{"key":"pone.0306044.ref008","doi-asserted-by":"crossref","first-page":"101675","DOI":"10.1016\/j.pmedr.2021.101675","article-title":"Effectiveness and costs of an implemented primary HPV cervical screening programme in Sweden\u2013A population based cohort study.","volume":"25","author":"L Bergengren","year":"2022","journal-title":"Preventive Medicine Reports"},{"key":"pone.0306044.ref009","doi-asserted-by":"crossref","first-page":"e068582","DOI":"10.1136\/bmj-2021-068582","article-title":"National experience in the first two years of primary human papillomavirus (HPV) cervical screening in an HPV vaccinated population in Australia: observational study.","author":"MA Smith","year":"2022","journal-title":"BMJ"},{"key":"pone.0306044.ref010","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/ijc.33850","article-title":"Switching clinic-based cervical cancer screening programs to human papillomavirus self-sampling: A cost-effectiveness analysis of vaccinated and unvaccinated Norwegian women","volume":"150","author":"K Pedersen","year":"2022","journal-title":"International Journal of Cancer"},{"key":"pone.0306044.ref011","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1111\/1471-0528.16610","article-title":"Introducing human papillomavirus (HPV) primary testing in the age of HPV vaccination: projected impact on colposcopy services in Wales","volume":"128","author":"F Pesola","year":"2021","journal-title":"BJOG: An International Journal of Obstetrics & Gynaecology."},{"key":"pone.0306044.ref012","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/S2468-2667(18)30183-X","article-title":"The projected timeframe until cervical cancer elimination in Australia: a modelling study","volume":"4","author":"MT Hall","year":"2019","journal-title":"The Lancet Public Health"},{"key":"pone.0306044.ref013","volume-title":"European guidelines for quality assurance in cervical cancer screening: second edition: supplements","author":"European Commission, Directorate-General for Health and Food Safety","year":"2015"},{"key":"pone.0306044.ref014","volume-title":"In: Australian Government Department of Health and Aged Care [Internet]","author":"Australian Government Department of Health and Aged Care.","year":"2023"},{"key":"pone.0306044.ref015","journal-title":"Primary HPV test\u2014now also for women under 34"},{"key":"pone.0306044.ref016","year":"2023","journal-title":"What is cervical screening? In: nhs.uk [Internet]"},{"key":"pone.0306044.ref017","article-title":"Gynekologisk cellprovskontroll [Swedish].","journal-title":"In: Cancerfonden [Internet]."},{"key":"pone.0306044.ref018","unstructured":"Nordcan 2.0. [cited 14 Sep 2023]. Available: https:\/\/nordcan.iarc.fr\/en\/factsheets"},{"key":"pone.0306044.ref019","first-page":"655","article-title":"The Danish Quality Database for Cervical Cancer Screening","author":"C. Rygaard","year":"2016"},{"key":"pone.0306044.ref020","author":"E. Lynge","year":"2017","journal-title":"Trial23\u2014A Method Study on the Use of Primary HPV-testing With Cytology Triage in Women Offered HPV-vaccination as Girls"},{"key":"pone.0306044.ref021","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-020294","article-title":"Danish method study on cervical screening in women offered HPV vaccination as girls (Trial23): A study protocol.","volume":"8","author":"LH Thamsborg","year":"2018","journal-title":"BMJ Open"},{"key":"pone.0306044.ref022","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1080\/14760584.2018.1509001","article-title":"HPV-vaccination impact in Denmark: is the vaccine working?","volume":"17","author":"E Lynge","year":"2018","journal-title":"Expert Review of Vaccines."},{"key":"pone.0306044.ref023","article-title":"Forebyggelse, udredning og behandling af dysplasi p\u00e5 Cervix.","author":"Dansk Selskab for Gyn\u00e6kologi og Obstetrik (DSOG).","year":"2022","journal-title":"Guideline [in Danish]."},{"key":"pone.0306044.ref024","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1002\/ijc.33157","article-title":"Prevalence of high-risk human papillomavirus after HPV-vaccination in Denmark","volume":"147","author":"E Lynge","year":"2020","journal-title":"International Journal of Cancer"},{"key":"pone.0306044.ref025","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12905-019-0743-0","article-title":"HPV testing for cervical cancer screening: technical improvement of laboratory logistics and good clinical performance of the cobas 6800 in comparison to the 4800 system.","volume":"19","author":"H Frayle","year":"2019","journal-title":"BMC Women\u2019s Health."},{"key":"pone.0306044.ref026","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/cncy.22572","article-title":"Cytology interpretation after a change to HPV testing in primary cervical screening: Observational study from the English pilot","volume":"130","author":"Group for the HPS","year":"2022","journal-title":"Cancer Cytopathology"},{"key":"pone.0306044.ref027","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/cncy.21783","article-title":"Knowledge of the HPV status biases cytotechnologists\u2019 interpretation of Pap tests originally diagnosed as negative for intraepithelial lesion or malignancy","volume":"125","author":"EE Doxtader","year":"2017","journal-title":"Cancer Cytopathology"},{"key":"pone.0306044.ref028","article-title":"The impact of knowledge of HPV positivity on cytology triage in primary high-risk HPV screening","volume":"4","author":"CA Aitken","year":"2019","journal-title":"Journal of Medical Screening"},{"key":"pone.0306044.ref029","volume-title":"In: National Cancer Control Indicators [Internet].","author":"Australia C.","year":"2015"},{"key":"pone.0306044.ref030","article-title":"Acceleration of cervical cancer diagnosis with human papillomavirus testing below age 30: Observational study","volume":"150","author":"M Rebolj","year":"2021","journal-title":"International Journal of Cancer"},{"key":"pone.0306044.ref031","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/s41416-022-01791-w","article-title":"The impact of catch-up bivalent human papillomavirus vaccination on cervical screening outcomes: an observational study from the English HPV primary screening pilot","volume":"127","author":"M Rebolj","year":"2022","journal-title":"Br J Cancer"},{"key":"pone.0306044.ref032","author":"National Institution of Public Health (NIPH).","year":"2011","journal-title":"School survey 2010 [in Danish]."},{"key":"pone.0306044.ref033","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/j.vaccine.2019.12.019","article-title":"Resilience of HPV vaccine uptake in Denmark: Decline and recovery","volume":"38","author":"PR Hansen","year":"2020","journal-title":"Vaccine"},{"key":"pone.0306044.ref034","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1405044","article-title":"A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women","volume":"372","author":"EA Joura","year":"2015","journal-title":"N Engl J Med"},{"key":"pone.0306044.ref035","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1038\/bjc.2013.647","article-title":"Type- and age-specific distribution of human papillomavirus in women attending cervical cancer screening in Finland","volume":"109","author":"MK Leinonen","year":"2013","journal-title":"Br J Cancer"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0306044","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T18:40:10Z","timestamp":1719340810000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0306044"}},"subtitle":[],"editor":[{"given":"Maria Lina","family":"Tornesello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,6,25]]},"references-count":35,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6,25]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0306044","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,25]]}}}